Gregory M. Weinhoff - Jun 2, 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Financial Officer
Signature: /s/ Marella Thorell, attorney-in-fact
Stock symbol: CNTA
Transactions as of: Jun 2, 2021
Transactions value $: $200,000
Form type: 4
Date filed: 6/4/2021, 05:00 PM
Previous filing: Jun 4, 2021
Next filing: Feb 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Purchase	$200K	+10K		$20.00	10K	Jun 2, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Share Option (right to buy)	Award	$0	+959K		$0.00	959K	Mar 4, 2021	Ordinary Shares	959K	$5.84	Direct	F1, F3, F4, F5, F6
transaction	CNTA	Share Option (right to buy)	Gift	$0	-320K	-33.33%	$0.00	639K	Apr 8, 2021	Ordinary Shares	320K	$5.84	Direct	F1, F3, F4, F5, F6, F7
transaction	CNTA	Share Option (right to buy)	Gift	$0	+320K		$0.00	320K	Apr 8, 2021	Ordinary Shares	320K	$5.84	See footnote	F1, F3, F4, F5, F6, F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Pursuant to maximum allowed participation in the Directed Share Program.
F3	On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.
F4	This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F5	25% of the shares subject to such option shall vest and become exercisable on March 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F6	Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F7	The Reporting Person transferred and assigned this option for no consideration to the Gregory Weinhoff 2017 Trust, a spousal lifetime access trust ("SLAT").
F8	Held by the SLAT, of which the Reporting Person's spouse and another immediate family member are trustees. The beneficiaries of the trust are the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of the securities held by the SLAT.